The present invention relates to a method for preparing substituted 3-(2-anilino-1-cyclohexyl-1H-benzimidazol-5-yl)propanoic acid derivatives of the general formula (I) in which R1 represents a hydrogen atom or R1 represents a group selected from the series of C1-C3-alkyl-, C1-C3-alkoxy-, C1-C3-haloalkyl- and C1-C3-haloalkoxy-, R2 represents a hydrogen atom or a C1-C3-alkyl group, R3 represents a hydrogen atom or a C1-C3-alkyl group, R4 represents a cyclohexyl group, which is optionally singly or multiply substituted by a C1-C3-alkyl group, and R5 represents a hydrogen atom or a C1-C6-alkyl group； and also intermediates which may be used to prepare substituted 3-(2-anilino-1- cyolohexyl-1H-benzimidazol-5-yl)propanoic acid derivatives. The present invention also relates to a crystalline form of 3-(2-{[4-(trifluoromethoxy)phenyl]amino}-1-[(1R,5R)-3,3,5-trimethylcyclohexyl]-1H-benzimidazol-5-yl)propanoic acid, pharmaceutical compositions comprising this crystalline form, and also the use of this crystalline form for preparing a medicament for the treatment of a disease.本發明係關於一種用於製備通式(I)之經取代之3-(2-苯胺-1-環己基-1H-苯并咪唑-5-基)丙酸衍生物的方法其中R1 表示氫原子或R1表示選自C1-C3烷基-、C1-C3烷氧基-、C1-C3鹵烷基-及C1-C3鹵烷氧基-之系列的基團，R2 表示氫原子或C1-C3烷基，R3 表示氫原子或C1-C3烷基，R4 表示環己基，其視情況經C1-C3烷基單取代或多取代，及R5 表示氫原子或C1-C6烷基；以及可用於製備經取代之3-(2-苯胺-1-環己基-1H-苯并咪唑-5-基)丙酸衍生物之中間物。本發明亦關於3-(2-{[4-(三氟甲氧基)苯基]胺基}-1-[(1R,5R)-3,3,5-三甲基環己基]-1H-苯并咪唑-5-基)丙酸之結晶形態、包含此結晶形態之醫藥組合物以及此結晶形態用於製備用以治療疾病之藥劑的用途。
